![Turmeric Hack Weight Loss Reviews [Lipozem BHB Complaints & Side Effects Ingredients] Fat Loss Support Supplement](https://i3.wp.com/ml.globenewswire.com/Resource/Download/75c572b8-a2bf-48dd-aa4b-9804597a64e2?w=150&resize=150,150&ssl=1 "Turmeric Hack Weight Loss Reviews [Lipozem BHB Complaints & Side Effects Ingredients] Fat Loss Support Supplement")
Recover Red Introduces Portable Red Light Therapy Solution: The Power Stack
PITTSBURGH, Dec. 26, 2024 (GLOBE NEWSWIRE) -- The widespread availability of Red…
Avextra Backs Landmark Psilocybin Therapy Study in Palliative Care
December 20, 2024 12:00 ET | Source: Avextra Pharma GmbH News Release…
Mesoblasts RYONCIL is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy
December 18, 2024 19:08 ET | Source: Mesoblast Limited RYONCIL (remestemcel-L) is…
HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS and TAGRISSO Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 11, 2024 (GLOBE…
Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium
December 11, 2024 07:05 ET | Source: Celcuity Inc. Median overall survival…
TECVAYLI (teclistamab) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma
100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD…
Five-year results confirm Roches Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma
Exploratory long-term follow-up analysis of the phase III POLARIX study indicated a…
Investigational Epcoritamab (DuoBody CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Media ReleaseCOPENHAGEN, Denmark; December 7, 2024 Results show 96 percent overall response…
Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
Data from the ongoing Phase 1/2 ATALANTA-1 study in a heavily pretreated…
New Phase IIIB data shows Novartis Fabhalta improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy
In the Phase IIIB APPULSE-PNH study, oral Fabhalta® (iptacopan) improved the average…